Diabetes
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Communication Preferences
Sign Out
Sign In | Create Account
  • Diabetes Home
    • Products
      Diabetes Treatments
    • Professional Resources
      Product Resources Library Insulin & Type 1 Diabetes
    • Professional Training
      Insulin Pen Training
  • Sample Requests
    • Diabetes Education
      Clinical Education Library Diabetes Risk Assessment Tool
    • Treatment Guidelines
      ADA Standards of Care AACE Diabetes Guidelines
    • Additional Resources
      Utilizing Your EHR Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Library
    • Prescription Savings & Coverage
      Savings Cards Insurance Coverage Affordability Resources
    • Support Program
      Diabetes Management
  • Sign In
    Create Account
    • Account Settings
    • Communication Preferences
    • Sign Out
    Medical Information
    Non-US Health Care Professionals
Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL logo
Important Safety Information | Patient Site
Prescribing Information
    • How Does Tresiba® Work?
    • Product Profile
    • Tresiba® and Type 1
    • Hear from Your Peers
    • Frequently Asked Questions
    • Type 2 Efficacy and Safety
    • Type 1 Efficacy and Safety
    • Hypoglycemia Facts
    • DEVOTE Study: MACE and Severe Hypoglycemia
    • SWITCH 2 Study: Hypoglycemia Data
    • Starting Adult Patients
    • Starting Pediatric Patients
    • Dose Timing Guidance
    • Tresiba® FlexTouch® and Vial
  • Cost and Coverage
    • Samples
    • Tresiba® Sample Starts
    • Patient Support
    • For Pharmacists
    • Video Library
Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL logo

Prescribing Information
Important Safety Information | Patient Site

Filling Tresiba®  (insulin degludec) prescriptions: What you need to know

Tresiba® is a once-daily, long-acting insulin indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.1 Tresiba® comes in 3 administration options: Tresiba® FlexTouch® U-100, Tresiba® FlexTouch®  U-200, and a U-100 10-mL vial.1

Request Tresiba® samples

Savings information     |     Tresiba® FlexTouch® Instructions For Use     |     Tresiba® facts

Savings information

Tresiba® FlexTouch® Instructions For Use

Tresiba® facts

Use tabs below to see more information about each administration option.

Tresiba® U-100 packaging

Concentration

100 units/mL

Pens per package

5

Volume per pen

3 mL

Units of insulin per pen

300 units

Units of insulin per package

1500 units

Max dose per injection

80 units

Dose increment

1 unit

NDC number

0169-2660-15

Concentration

100 units/mL

Pens per package

5

Volume per pen

3 mL

Units of insulin per pen

300 units

Units of insulin per package

1500 units

Max dose per injection

80 units

Dose increment

1 unit

NDC number

0169-2660-15

Don’t forget to order NovoFine® Plus disposable needles. The 32G, 4-mm pen needle is Novo Nordisk’s shortest and thinnest needle available.a

aNeedles are sold separately and may require a prescription in some states.

Tresiba® U-200 packaging

Concentration

200 units/mL

Pens per package

3

Volume per pen

3 mL

Units of insulin per pen

600 units

Units of insulin per package

1800 units

Max dose per injection

160 units

Dose increment

2 units

NDC number

0169-2550-13

Concentration

200 units/mL

Pens per package

3

Volume per pen

3 mL

Units of insulin per pen

600 units

Units of insulin per package

1800 units

Max dose per injection

160 units

Dose increment

2 units

NDC number

0169-2550-13

Don’t forget to order NovoFine® Plus disposable needles. The 32G, 4-mm pen needle is Novo Nordisk’s shortest and thinnest needle available.b

bNeedles are sold separately and may require a prescription in some states.

Tresiba® U-100, 10 mL vial

Concentration

100 units/mL

Vials per package

1 vial

Volume per vial

10 mL

Units of insulin per vial

1000 units

NDC number

0169-2662-11

Concentration

100 units/mL

Vials per package

1 vial

Volume per vial

10 mL

Units of insulin per vial

1000 units

NDC number

0169-2662-11

An option for patients who prefer vials or children who require fewer than 5 units a day.

Download the Insulin Portfolio Pharmacy Reference Guide

Tresiba® savings card image

Eligible patients pay as little as $25 or no more than $99 per prescriptionc

Direct patients to TresibaSavings.com to get a savings card ›

See all the Tresiba® affordability offerings at NovoCare.com

cEligibility and other restrictions apply.

How to use the Tresiba® FlexTouch®

Help your patients learn how to use Tresiba® FlexTouch® U-100 and U-200 by directing them to these easy-to-follow videos that introduce them to the pen and illustrate how they can administer Tresiba®.

View illustrated IFU
See storage information
How to Use Tresiba® FlexTouch® U-100 Video
(13:51)

View Tresiba® Prescribing Information

How to Use Tresiba® FlexTouch® U-200 Video
(14:00)

View Tresiba® Prescribing Information

View illustrated IFU
See storage information

Other facts about Tresiba®1:

Injected subcutaneously once daily and, for adults, at any time of day

  • Instruct adult patients who miss a dose of Tresiba® to inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule
  • Tresiba® must be dosed at the same time each day for pediatric patients. Instruct pediatric patients who miss a dose of Tresiba® to contact their health care provider for guidance and to monitor blood glucose levels more frequently until the next scheduled dose
  • Instruct adult patients to ensure that at least 8 hours have elapsed between consecutive Tresiba® injections

The recommended time between dose increases is 3 to 4 days

  • No dose conversion needed

Opened (in-use) Tresiba® can be kept at room temperature (below 86°F), away from direct heat and light, or refrigerated (36°F to 46°F) for 56 days (8 weeks)

  • The dose window for the Tresiba® FlexTouch® U-100 and U-200 pens shows the number of units to be delivered
  • The vial offers an option for patients who prefer vials or children who require fewer than 5 units a day 

Leading a healthier life with diabetes can be tough, but Cornerstones4Care® is here to help

Your patients have the option to speak with a Diabetes Health Coach who is ready to assist them by phone, text, or email, on a schedule that’s convenient for them! Their Health Coach can:

  • Answer questions one on one
  • Provide healthy eating ideas and tips to help your patients stay strong
  • Help your patients stay motivated to set and reach their goals

Encourage patients taking Tresiba® to register for support at Tresiba.com

Indications and Usage for Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL

Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
  • Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba® 
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • There are certain drugs that may cause clinically significant drug interactions with Tresiba®.
    • Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
    • Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
    • Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
    • Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine

 

Please click here for Tresiba® Prescribing Information.

Reference:

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; November 2019.
Diabetes
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Diabetes Home
  • Product Information
    Products
    • Diabetes Treatments
    Professional Resources
    • Product Resources Library
      Insulin & Type 1 Diabetes
    Professional Training
    • Insulin Pen Training
  • Sample Requests
  • Professional Education
    Diabetes Education
    • Clinical Education Library
      Diabetes Risk Assessment Tool
    Treatment Guidelines
    • ADA Standards of Care
      AACE Diabetes Guidelines
    Additional Resources
    • Utilizing Your EHR
      Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Library
    Prescription Savings & Coverage
    • Savings Cards
      Insurance Coverage
      Affordability Resources
    Support Program
    • Diabetes Management

Cornerstones4Care®, FlexTouch®, Levemir®, NovoFine®, NovoLog®, PenFill®, and Tresiba® are registered trademarks and novoMEDLINK™ is a trademark of Novo Nordisk A/S.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective owners.

Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved. US21TSM00200 January 2022

Quick links

Request medication samples

Diabetes treatment guidelines

Patient savings card offer

Patient support program